Cargando…

Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement

AIMS: This study investigated the prognostic value of plasma volume status (PVS) in patients who underwent transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS: Plasma volume status was calculated in 2588 patients who underwent TAVR using data from the Japanese multicentre registry. Al...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimura, Tetsuro, Yamamoto, Masanori, Yamaguchi, Ryo, Adachi, Yuya, Sago, Mitsuru, Tsunaki, Tatsuya, Kagase, Ai, Koyama, Yutaka, Otsuka, Toshiaki, Yashima, Fumiaki, Tada, Norio, Naganuma, Toru, Yamawaki, Masahiro, Yamanaka, Futoshi, Shirai, Shinichi, Mizutani, Kazuki, Tabata, Minoru, Ueno, Hiroshi, Takagi, Kensuke, Watanabe, Yusuke, Hayashida, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120354/
https://www.ncbi.nlm.nih.gov/pubmed/33666353
http://dx.doi.org/10.1002/ehf2.13270
_version_ 1783692062590238720
author Shimura, Tetsuro
Yamamoto, Masanori
Yamaguchi, Ryo
Adachi, Yuya
Sago, Mitsuru
Tsunaki, Tatsuya
Kagase, Ai
Koyama, Yutaka
Otsuka, Toshiaki
Yashima, Fumiaki
Tada, Norio
Naganuma, Toru
Yamawaki, Masahiro
Yamanaka, Futoshi
Shirai, Shinichi
Mizutani, Kazuki
Tabata, Minoru
Ueno, Hiroshi
Takagi, Kensuke
Watanabe, Yusuke
Hayashida, Kentaro
author_facet Shimura, Tetsuro
Yamamoto, Masanori
Yamaguchi, Ryo
Adachi, Yuya
Sago, Mitsuru
Tsunaki, Tatsuya
Kagase, Ai
Koyama, Yutaka
Otsuka, Toshiaki
Yashima, Fumiaki
Tada, Norio
Naganuma, Toru
Yamawaki, Masahiro
Yamanaka, Futoshi
Shirai, Shinichi
Mizutani, Kazuki
Tabata, Minoru
Ueno, Hiroshi
Takagi, Kensuke
Watanabe, Yusuke
Hayashida, Kentaro
author_sort Shimura, Tetsuro
collection PubMed
description AIMS: This study investigated the prognostic value of plasma volume status (PVS) in patients who underwent transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS: Plasma volume status was calculated in 2588 patients who underwent TAVR using data from the Japanese multicentre registry. All‐cause mortality and heart failure hospitalization (HFH) within 2 years of TAVR were compared among the PVS quartiles (Q1, PVS < 5.5%; Q2, PVS 5.5–13.5%; Q3, PVS 13.5–21.0%; and Q4, PVS ≥ 21.0%). Subgroups were stratified by the PVS cut‐off value combined with the New York Heart Association (NYHA) class as follows: low PVS with NYHA I/II (n = 959), low PVS with NYHA III/IV (n = 845), high PVS with NYHA I/II (n = 308), and high PVS with NYHA III/IV (n = 476). The cumulative all‐cause mortality and HFH within 2 years of TAVR significantly increased with increasing PVS quartiles [8.5%, 16.8%, 19.2%, and 27.0% (P < 0.001) and 5.8%, 8.7%, 10.3%, and 12.9% (P < 0.001), respectively]. The high‐PVS group regardless of the NYHA class had a higher all‐cause mortality and HFH [9.6%, 18.2%, 24.5%, and 30.4% (P < 0.001) and 6.1%, 10.4%, 14.1%, and 11.3% (P < 0.001)]. In a Cox regression multivariate analysis, the PVS values of Q3 and Q4 had independently increased all‐cause mortality [hazard ratio (HR), 1.50 and 1.64 (P = 0.017 and P = 0.008), respectively], and Q4 had independently increased HFH (HR, 1.98, P = 0.005). The low PVS with NYHA III/IV, high PVS with NYHA I/II, and high PVS with NYHA III/IV also had significantly increased all‐cause mortality [HR, 1.45, 1.73, and 1.86 (P = 0.006, P = 0.002, and P < 0.001), respectively] and HFH [HR, 1.52, 2.21, and 1.70 (P = 0.049, P = 0.002, and P = 0.031), respectively]. CONCLUSIONS: Plasma volume status is useful for predicting all‐cause mortality and HFH after TAVR.
format Online
Article
Text
id pubmed-8120354
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81203542021-05-21 Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement Shimura, Tetsuro Yamamoto, Masanori Yamaguchi, Ryo Adachi, Yuya Sago, Mitsuru Tsunaki, Tatsuya Kagase, Ai Koyama, Yutaka Otsuka, Toshiaki Yashima, Fumiaki Tada, Norio Naganuma, Toru Yamawaki, Masahiro Yamanaka, Futoshi Shirai, Shinichi Mizutani, Kazuki Tabata, Minoru Ueno, Hiroshi Takagi, Kensuke Watanabe, Yusuke Hayashida, Kentaro ESC Heart Fail Original Research Articles AIMS: This study investigated the prognostic value of plasma volume status (PVS) in patients who underwent transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS: Plasma volume status was calculated in 2588 patients who underwent TAVR using data from the Japanese multicentre registry. All‐cause mortality and heart failure hospitalization (HFH) within 2 years of TAVR were compared among the PVS quartiles (Q1, PVS < 5.5%; Q2, PVS 5.5–13.5%; Q3, PVS 13.5–21.0%; and Q4, PVS ≥ 21.0%). Subgroups were stratified by the PVS cut‐off value combined with the New York Heart Association (NYHA) class as follows: low PVS with NYHA I/II (n = 959), low PVS with NYHA III/IV (n = 845), high PVS with NYHA I/II (n = 308), and high PVS with NYHA III/IV (n = 476). The cumulative all‐cause mortality and HFH within 2 years of TAVR significantly increased with increasing PVS quartiles [8.5%, 16.8%, 19.2%, and 27.0% (P < 0.001) and 5.8%, 8.7%, 10.3%, and 12.9% (P < 0.001), respectively]. The high‐PVS group regardless of the NYHA class had a higher all‐cause mortality and HFH [9.6%, 18.2%, 24.5%, and 30.4% (P < 0.001) and 6.1%, 10.4%, 14.1%, and 11.3% (P < 0.001)]. In a Cox regression multivariate analysis, the PVS values of Q3 and Q4 had independently increased all‐cause mortality [hazard ratio (HR), 1.50 and 1.64 (P = 0.017 and P = 0.008), respectively], and Q4 had independently increased HFH (HR, 1.98, P = 0.005). The low PVS with NYHA III/IV, high PVS with NYHA I/II, and high PVS with NYHA III/IV also had significantly increased all‐cause mortality [HR, 1.45, 1.73, and 1.86 (P = 0.006, P = 0.002, and P < 0.001), respectively] and HFH [HR, 1.52, 2.21, and 1.70 (P = 0.049, P = 0.002, and P = 0.031), respectively]. CONCLUSIONS: Plasma volume status is useful for predicting all‐cause mortality and HFH after TAVR. John Wiley and Sons Inc. 2021-03-05 /pmc/articles/PMC8120354/ /pubmed/33666353 http://dx.doi.org/10.1002/ehf2.13270 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research Articles
Shimura, Tetsuro
Yamamoto, Masanori
Yamaguchi, Ryo
Adachi, Yuya
Sago, Mitsuru
Tsunaki, Tatsuya
Kagase, Ai
Koyama, Yutaka
Otsuka, Toshiaki
Yashima, Fumiaki
Tada, Norio
Naganuma, Toru
Yamawaki, Masahiro
Yamanaka, Futoshi
Shirai, Shinichi
Mizutani, Kazuki
Tabata, Minoru
Ueno, Hiroshi
Takagi, Kensuke
Watanabe, Yusuke
Hayashida, Kentaro
Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement
title Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement
title_full Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement
title_fullStr Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement
title_full_unstemmed Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement
title_short Calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement
title_sort calculated plasma volume status and outcomes in patients undergoing transcatheter aortic valve replacement
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120354/
https://www.ncbi.nlm.nih.gov/pubmed/33666353
http://dx.doi.org/10.1002/ehf2.13270
work_keys_str_mv AT shimuratetsuro calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT yamamotomasanori calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT yamaguchiryo calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT adachiyuya calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT sagomitsuru calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT tsunakitatsuya calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT kagaseai calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT koyamayutaka calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT otsukatoshiaki calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT yashimafumiaki calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT tadanorio calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT naganumatoru calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT yamawakimasahiro calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT yamanakafutoshi calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT shiraishinichi calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT mizutanikazuki calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT tabataminoru calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT uenohiroshi calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT takagikensuke calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT watanabeyusuke calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT hayashidakentaro calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement
AT calculatedplasmavolumestatusandoutcomesinpatientsundergoingtranscatheteraorticvalvereplacement